{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:56:09Z","timestamp":1783180569463,"version":"3.54.6"},"reference-count":74,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The COVID-19 pandemic caused by the Coronavirus SARS-CoV-2 is a complex challenge for the existing scientific and medical landscape. It is an ongoing public health crisis, with over 245,373,039 confirmed cases globally, including 4,979,421 deaths as of 29 October 2021. Exploring molecular mechanisms correlated with the disease\u2019s severity has demonstrated significant factors of immune compromise, noted in diabetic patients with SARS-CoV-2 infections. Among diabetics, the altered function of the immune system allows for better penetration of the virus into epithelial cells, increased viral binding affinity due to hyperglycemia, reduced T cell function, decreased viral clearance, high risks of cytokine storm, and hyper-inflammatory responses, altogether increasing the susceptibility of these patients to an extreme COVID-19 disease course. Materials and Methods: This research involved a systematic literature search among various databases comprising PubMed and Google Scholar in determining credible studies about the effects of antidiabetic drugs on the high mortality rates among diabetic patients infected with COVID-19. The primary search found 103 results. Duplicated results, non-pertinent articles, and the unavailability of full text were excluded. Finally, we included 74 articles in our review. The inclusion criteria included articles published during 2020\u20132023, studies that reported a low risk of bias, and articles published in English. Exclusion criteria included studies published in non-peer-reviewed sources, such as conference abstracts, thesis papers, or non-academic publications. Results: Among the studied anti-diabetic drugs, Metformin, the Glucagon-like peptide 1 receptor agonist (GLP-1RA), and Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have demonstrated decreased mortality rates among diabetic patients infected with COVID-19. Insulin and Dipeptidyl peptidase 4 inhibitors (DPP-4i) have demonstrated increased mortality rates, while Sulfonylureas, Thiazolidinedione (TZD), and Alpha-glucosidase inhibitors (AGI) have demonstrated mortality-neutral results.<\/jats:p>","DOI":"10.3390\/medicina59101810","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T08:07:12Z","timestamp":1697011632000},"page":"1810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3379-8909","authenticated-orcid":false,"given":"Daniel","family":"Gonikman","sequence":"first","affiliation":[{"name":"Student of Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-0204","authenticated-orcid":false,"given":"Dmitrijs","family":"Kustovs","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Riga Stradins University, LV-1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: From pathophysiology to clinical management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14790","DOI":"10.1038\/s41598-020-71908-9","article-title":"Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025","volume":"10","author":"Lin","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108347","DOI":"10.1016\/j.diabres.2020.108347","article-title":"Diabetes and COVID-19: A systematic review on the current evidences","volume":"166","author":"Abdi","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kamyshnyi, O., Matskevych, V., Lenchuk, T., Strilbytska, O., Storey, K., and Lushchak, O. (2021). Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential. Biomed. Pharmacother., 144.","DOI":"10.1016\/j.biopha.2021.112230"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bica, I.-C., Pietro\u0219el, V.-A., Salmen, T., Diaconu, C.-T., Fierbinteanu Braticevici, C., Stoica, R.-A., Suceveanu, A.I., and Pantea Stoian, A. (2023). The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus\u2014A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087184"},{"key":"ref_6","first-page":"442","article-title":"Type 2 Diabetes and its Impact on the Immune System","volume":"16","author":"Berbudi","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11239-022-02667-9","article-title":"Metformin therapy in COVID-19: Inhibition of NETosis","volume":"54","author":"Kow","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.puhe.2021.11.007","article-title":"Clinical features, risk factors and a prediction model for in-hospital mortality among diabetic patients infected with COVID-19: Data from a referral centre in Iran","volume":"202","author":"Kabootari","year":"2022","journal-title":"Public Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21315\/mjms2023.30.3.7","article-title":"Risk Factors Associated with the Severity of COVID-19","volume":"30","author":"Martono","year":"2023","journal-title":"Malays. J. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101359","DOI":"10.1016\/j.diabet.2022.101359","article-title":"Protection by metformin against severe COVID-19: An in-depth mechanistic analysis","volume":"48","author":"Wiernsperger","year":"2022","journal-title":"Diabetes Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155196","DOI":"10.1016\/j.metabol.2022.155196","article-title":"Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis","volume":"131","author":"Nguyen","year":"2022","journal-title":"Metabolism"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ehjcvp\/pvac044","article-title":"Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis","volume":"9","author":"Ferrannini","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/dom.14329","article-title":"Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2","volume":"23","author":"Israelsen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"587801","DOI":"10.3389\/fendo.2021.587801","article-title":"Metformin and COVID-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit","volume":"12","author":"Ibrahim","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/wasj.2020.68","article-title":"Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)","volume":"2","author":"Lehrer","year":"2020","journal-title":"World Acad. Sci. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/1753-0407.13243","article-title":"Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis","volume":"14","author":"Bradley","year":"2022","journal-title":"J. Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12553-022-00660-z","article-title":"A review of COVID-19\u2019s impact on modern medical systems from a health organization management perspective","volume":"12","author":"Davis","year":"2022","journal-title":"Health Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"592439","DOI":"10.3389\/fphar.2020.592439","article-title":"Perspectives of Antidiabetic Drugs in Diabetes with Coronavirus Infections","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: A new perspective on an overlooked drug","volume":"20","author":"Nesti","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/1753-0407.13052","article-title":"COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?","volume":"12","author":"Bassendine","year":"2020","journal-title":"J. Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"p1306","DOI":"10.1136\/bmj.p1306","article-title":"COVID-19: Metformin reduces the risk of developing long term symptoms by 40%, study finds","volume":"381","author":"Wise","year":"2023","journal-title":"BMJ"},{"key":"ref_24","first-page":"e37487","article-title":"A Review of Hyperglycemia in COVID-19","volume":"15","author":"Zahedi","year":"2023","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.4239\/wjd.v12.i9.1550","article-title":"Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity","volume":"12","author":"Gangadharan","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40618-022-01951-y","article-title":"Insulin may increase disease severity and mortality of COVID-19 through Na(+)\/H(+) exchanger in patients with type 1 and type 2 diabetes mellitus","volume":"46","author":"Cure","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119371","DOI":"10.1016\/j.lfs.2021.119371","article-title":"Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study","volume":"275","author":"Cheng","year":"2021","journal-title":"Life Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1002834","DOI":"10.3389\/fendo.2022.1002834","article-title":"Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1038\/s41598-022-09639-2","article-title":"Metformin is associated with favorable outcomes in patients with COVID-19 and type 2 diabetes mellitus","volume":"12","author":"Ma","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ma, Z., and Krishnamurthy, M. (2023). Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0282210"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Pafundi, P.C., Galiero, R., Gjeloshi, K., Masini, F., Acierno, C., Di Martino, A., Albanese, G., Alfano, M., and Rinaldi, L. (2020). Metformin: A Potential Therapeutic Tool for Rheumatologists. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090234"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101216","DOI":"10.1016\/j.diabet.2020.101216","article-title":"Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19","volume":"47","author":"Lalau","year":"2021","journal-title":"Diabetes Metab."},{"key":"ref_33","first-page":"317","article-title":"Metformin therapy and severity and mortality of SARS-CoV-2 infection: A meta-analysis","volume":"10","author":"Oscanoa","year":"2021","journal-title":"Clin. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mirabelli, M., Chiefari, E., Puccio, L., Foti, D.P., and Brunetti, A. (2020). Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17103664"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.14648","article-title":"Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy","volume":"24","author":"Foresta","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/0960327120947452","article-title":"Metformin protects against diabetes-induced heart injury and dunning prostate cancer model","volume":"40","author":"Bayrak","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/thoraxjnl-2021-217561","article-title":"Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19","volume":"77","author":"Bridges","year":"2022","journal-title":"Thorax"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4269\/ajtmh.20-0375","article-title":"Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis","volume":"103","author":"Luo","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_39","first-page":"100142","article-title":"Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial","volume":"6","author":"Reis","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jamda.2020.10.031","article-title":"Metformin is Associated with Decreased 30-Day Mortality among Nursing Home Residents Infected with SARS-CoV2","volume":"22","author":"Lally","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00592-020-01666-7","article-title":"Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: An NHIS-COVID-19 database cohort study","volume":"58","author":"Oh","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/14740338.2021.1970744","article-title":"The role of GLP-1 receptor agonists during COVID-19 pandemia: A hypothetical molecular mechanism","volume":"20","author":"Banerjee","year":"2021","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1871530321666210809153558","article-title":"Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19","volume":"22","author":"Alshanwani","year":"2022","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100312","DOI":"10.1016\/j.obmed.2020.100312","article-title":"Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment","volume":"22","author":"Pang","year":"2021","journal-title":"Obes. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"109031","DOI":"10.1016\/j.diabres.2021.109031","article-title":"Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression","volume":"179","author":"Hariyanto","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.2337\/db21-0385","article-title":"Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study","volume":"70","author":"Nyland","year":"2021","journal-title":"Diabetes"},{"key":"ref_47","first-page":"27","article-title":"Hypoglycemic agents and potential anti-inflammatory activity","volume":"9","author":"Kothari","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"155221","DOI":"10.1016\/j.metabol.2022.155221","article-title":"COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong","volume":"133","author":"Koufakis","year":"2022","journal-title":"Metabolism"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41420-021-00625-7","article-title":"Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFkappaB pathway","volume":"7","author":"Wang","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pcd.2021.12.008","article-title":"Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19\u2014A systematic review and meta-analysis","volume":"16","author":"Zein","year":"2022","journal-title":"Prim. Care Diabetes"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.isci.2020.101160","article-title":"The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike","volume":"23","author":"Li","year":"2020","journal-title":"iScience"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40200-021-00833-z","article-title":"Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: Data from the COVID-PREDICT cohort study in The Netherlands","volume":"20","author":"Meijer","year":"2021","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/03007995.2022.2027141","article-title":"Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?\u2014Targeting hyperinflammation","volume":"38","author":"Alshnbari","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/dom.14296","article-title":"Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study","volume":"23","author":"Kosiborod","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","unstructured":"Padda, I.S., Mahtani, A.U., and Parmar, M. (2023). StatPearls, StatPearls."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.hrtlng.2020.09.002","article-title":"SGLT-2 inhibitors as cardioprotective agents in COVID-19","volume":"49","author":"Gupta","year":"2020","journal-title":"Heart Lung"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s11096-021-01256-9","article-title":"Sodium-glucose co-transporter 2 inhibitors in COVID-19: Meeting at the crossroads between heart, diabetes and infectious diseases","volume":"43","author":"Koufakis","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Salmen, T., Pietrosel, V.A., Mihai, B.M., Bica, I.C., Teodorescu, C., Paunescu, H., Coman, O.A., Mihai, D.A., and Pantea Stoian, A. (2022). Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102624"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2244652","DOI":"10.1001\/jamanetworkopen.2022.44652","article-title":"Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis","volume":"5","author":"Zhu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.arcmed.2021.08.002","article-title":"Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis","volume":"53","author":"Han","year":"2022","journal-title":"Arch. Med. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.aace.2020.11.019","article-title":"Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients with Type 2 Diabetes Taking SGLT2 Inhibitors","volume":"7","author":"Vitale","year":"2021","journal-title":"AACE Clin. Case Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2215\/CJN.03250322","article-title":"Learnings from Throwing Paint at the Wall for COVID-19 with an SGLT2 Inhibitor","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_64","unstructured":"McIver, L.A., Preuss, C.V., and Tripp, J. (2023). StatPearls, StatPearls."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e00301","DOI":"10.1002\/edm2.301","article-title":"Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus","volume":"5","author":"Li","year":"2022","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.dsx.2020.05.007","article-title":"Role of oxidized LDL-induced \u201ctrained macrophages\u201d in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis","volume":"14","author":"Erol","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.dsx.2020.06.015","article-title":"Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?","volume":"14","author":"Jagat","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1172\/JCI11705","article-title":"Unraveling the mechanism of action of thiazolidinediones","volume":"106","author":"Kahn","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_69","first-page":"122","article-title":"Pioglitazone Alters Ace\/Ace 2 Balance to Favour Ace2 Independently of Glycaemia Levels in Diabetic Rat Heart","volume":"78","author":"Kralova","year":"2023","journal-title":"Pharmazie"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Fierro, P., Mart\u00edn, D., Pariente, E., Garc\u00eda-Garrido, A.B., Basterrechea, H., Petitta, B., Bianconi, C., Herr\u00e1n, S., Berrueta, A., and Jorr\u00edn, A. (2023). Post-COVID-19 syndrome and insulin resistance 20 months after a mild COVID-19. medRxiv.","DOI":"10.1101\/2023.04.17.23288637"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"649525","DOI":"10.3389\/fendo.2021.649525","article-title":"COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course","volume":"12","author":"Landstra","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Nour, T.Y., and Altintas, K.H. (2023). Effect of the COVID-19 pandemic on obesity and it is risk factors: A systematic review. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15833-2"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Baeradeh, N., Ghoddusi Johari, M., Moftakhar, L., Rezaeianzadeh, R., Hosseini, S.V., and Rezaianzadeh, A. (2022). The prevalence and predictors of cardiovascular diseases in Kherameh cohort study: A population-based study on 10,663 people in southern Iran. BMC Cardiovasc. Disord., 22.","DOI":"10.1186\/s12872-022-02683-w"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.2337\/dc22-0616","article-title":"Diabetes-related excess mortality in Mexico: A comparative analysis of national death registries between 2017\u20132019 and 2020","volume":"45","author":"Wexler","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:05:04Z","timestamp":1760130304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":74,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["medicina59101810"],"URL":"https:\/\/doi.org\/10.3390\/medicina59101810","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}